Evommune Inc., Completes $83 Million Series A Financing To Advance Development Of Unique Chronic Inflammation Pipeline
Amount Raised
$83 Million
Round Type
Series A
Palo AltoBiotechnologyHealth CareDescription
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced the completion of an $83 million Series A financing which included Andera Partners and LSP, who joined forces with a global syndicate of investors and existing investor, Pivotal bioVenture Partners. The financing enables Evommune to continue the research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases.
Quick answer
Evommune raised $83 Million in a Series A round, dated September 9, 2021. Evommune is based in Palo Alto, California, United States.
- How much did Evommune raise?
- Evommune raised $83 Million in a Series A round on September 9, 2021.
- What does Evommune do?
- Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases.
- Where is Evommune based and how big is it?
- Evommune is based in Palo Alto, California, United States. Fundz records about 45 employees.
- Who are the decision-makers at Evommune?
- Fundz holds 1 contact at Evommune. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Evommune that raised within 45 days of this round, from Fundz verified event records.
- Trait Biosciences Inc. raised $619K (Seed) on October 22, 2021.
- CHARM Therapeutics raised $13M on October 22, 2021.
- ReCode Therapeutics raised an undisclosed amount (Series B) on October 21, 2021.
- Leucid Bio raised $15M (Series A) on October 21, 2021.
- LifeLens Technologies raised $78K (Pre-Seed) on October 21, 2021.
- Your Super, Inc. raised $1.5M (Seed) on October 20, 2021.
Who to call at Evommune, and when
A new round usually means Evommune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Evommune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Evommune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Evommune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Evommune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEvommune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.